BioCentury
ARTICLE | Clinical News

Telcyta: Phase III ongoing

October 22, 2007 7:00 AM UTC

FDA lifted a partial hold on the Phase III ASSIST-5 trial of Telcyta plus doxorubicin as second-line therapy for platinum-refractory or resistant ovarian cancer. TELK said it would perform an interim ...